LEO Pharma

LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. Together, we reach far beyond the skin.

Disclaimer:

This site is intended for discussions about LEO Pharma and the various initiatives LEO Pharma is involved in. Due to regulations, discussions about pharmaceutical products are not allowed on this site. All content must be factual and non-promotional.

LEO Pharma reserves the right to moderate or remove any content that may be inconsistent with legislation, industry ethics and regulations and LEO Pharma’s values, including:

- profane or vulgar language

- insulting or offensive comments, such as displays of racism, calls to violence, hate propaganda, etc.

- commercial or political advertising

- copyright infringements, or any violation of the rights of external parties

- automatically-generated content i.e. spam

- wrong/false statements

For more information about our social media principles, please visit https://www.leo-pharma.com/social-media-principles